Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HS-10384 in menopausal women with moderate to severe vasomotor symptoms
CTR20241214Phase 2Terminated
- Sponsor
- Changzhou Hengbang Pharmaceutical
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10384 in vasomotor symptoms, sponsored by Changzhou Hengbang Pharmaceutical. Started Apr 2024; status: terminated.
02
Drugs
HS-10384
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on CTR20241214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241214.